Estrogen Receptor was positive, Progesterone Receptor was negative and HER2 by IHC was 3+ in what was called DCIS Oncologist denied the role of Herceptin as a part of therapy as HER2 expression was in DCIS only with no invasive component present. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.